Begin typing your search above and press return to search.
proflie-avatar
Login
exit_to_app
The disillusionment of the saffron brigades
access_time 27 April 2024 4:43 AM GMT
The pro-Palestine protests on American campuses
access_time 26 April 2024 4:00 AM GMT
Let Kerala set the direction for the country
access_time 25 April 2024 5:24 AM GMT
Here is what Modi juggernaut cannot understand
access_time 24 April 2024 5:07 AM GMT
Warnings in the Human Development Index
access_time 23 April 2024 12:47 PM GMT
Rule of law and law-breaking nations
access_time 22 April 2024 4:06 AM GMT
DEEP READ
Schools breeding hatred
access_time 14 Sep 2023 10:37 AM GMT
Ukraine
access_time 16 Aug 2023 5:46 AM GMT
Ramadan: Its essence and lessons
access_time 13 March 2024 9:24 AM GMT
exit_to_app
Homechevron_rightIndiachevron_rightAntacid Digene Gel...

Antacid Digene Gel batches recalled after DCGI issues advisory

text_fields
bookmark_border
Antacid Digene Gel batches recalled after DCGI issues advisory
cancel

New Delhi: Drug Controller General of India (DCGI) Rajeev Singh Raghuvanshi has issued an advisory to discontinue the use of antacid Digene Gel manufactured by drugmaker Abbott India at its Goa unit.

The DCGI has issued the advisory following a complaint on August 9, alleging that one bottle of Digene Gel mint flavour is of regular taste (sweet) and light pink colour whereas another bottle of the same batch was of white colour with bitter taste and pungent odour.

The DCGI said the impugned product manufactured at the Goa facility may be unsafe and its use may result in adverse reactions.

"The doctors and healthcare professionals should carefully prescribe and educate their patients to discontinue the use and for reporting of any ADRs (adverse drug reactions) arising due to consumption of the said product. Healthcare professionals should promptly report any suspicious cases of adverse events linked to this product," read the advisory issued by Dr Raghuvanshi recently.

It further said the said product within active shelf life to be removed from the distribution.

The DCGI also asked states/union territories' drug controllers to keep a strict vigil on the movement, sale, distribution, stock of the drug products in the market, draw samples if the product lying in market and initiate necessary action as per the provisions of the Drugs and Cosmetics Act and Rules.

Abbott India in its letter to DCGI on August 11 said it had voluntarily recalled the impugned product and also stopped production of all variants of Digene Gel manufactured at their Goa facility, as per the regulator.

Meanwhile, Abbott in a statement said, “Abbott in India has voluntarily recalled Digene Gel antacid medicine manufactured at our Goa site, due to isolated customer complaints on taste and odour. There have been no reports of patient health concerns."

"Other forms of Digene, such as tablets and stick packs are not impacted and Digene Gel manufactured at our other production site is not affected and continues to be available in sufficient quantities to meet current demand," it said.


With IANS inputs

Also Read: 2023 likely to be the hottest year on record, climate breakdown underway


Show Full Article
TAGS:DCGIIndia NewsDigene Gel
Next Story